近日，美国Amgen公司Lawren C. Wu、Jackson G. Egen等研究人员总结了抗肿瘤免疫疗法中临床试验的启示。2020年1月14日，国际知名学术期刊《免疫》发表了这一成果。

研究人员表示，靶向T细胞抑制性检查点蛋白CTLA-4和PD（L）1的疗法在多种癌症中均有效，从而降低了肿瘤负担，并增加了部分患者的长期生存率。这些免疫疗法显著而广泛的作用已经促进了其他通过对肿瘤微环境中的T细胞、髓样细胞和其他细胞类型调节抗肿瘤免疫力疗法的临床研究。这些较新研究性疗法的临床效力混杂在一起，有些疗法显示出希望，而另一些疗法则未显示出明显的功效。

研究人员总结了除抗CTLA-4和抗PD（L）1以外的癌症免疫疗法的部分近期临床研究结果，并讨论了这些结果如何为调节人类抗肿瘤免疫力提供新见解。

附：英文原文

Title: Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials

Author: Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu

Issue&Volume: 2020/01/14

Abstract: Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD(L)1 are efficacious across a broad range of cancers, resulting in reductions in tumor burden and increased long-term survival in subsets of patients. The significant and wide-ranging effects of these immunotherapies have prompted the clinical investigation of additional therapies that modulate anti-tumor immunity through effects on T cells, myeloid cells, and other cell types within the tumor microenvironment. The clinical activity of these newer investigational therapies has been mixed, with some therapeutics showing promise but others not exhibiting appreciable efficacy. In this review, we summarize the results of select recent clinical studies of cancer immunotherapies beyond anti-CTLA-4 and anti-PD(L)1 and discuss how these results are providing new insights into the regulation of human anti-tumor immunity.

DOI: 10.1016/j.immuni.2019.12.010

Source: https://www.cell.com/immunity/fulltext/S1074-7613(19)30529-1